Literature DB >> 16933103

High prevalence of metabolic syndrome in patients with ankylosing spondylitis.

Domenico Malesci1, Alferio Niglio, Gianna Angela Mennillo, Rosario Buono, Gabriele Valentini, Giovanni La Montagna.   

Abstract

The objective of this work is to investigate the occurrence of atherosclerosis and metabolic syndrome (MetS) in ankylosing spondylitis (AS) patients (pts). Twenty-four consecutive AS pts (men, 87.5%; median age, 50.5 years; median disease duration, 16.5 years), fulfilling the modified 1984 New York criteria for AS criteria, and 19 age- and sex-matched controls were investigated. Clinical atherosclerosis was evaluated by physical examination for cardiovascular (CV) diseases and history or drug use for CV events. Subclinical atherosclerosis was detected by mean intima media thickness (a-IMT) and maximum IMT (max-IMT) of carotid arteries using ultrasonography. Laboratory investigations including fasting plasma glucose, total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides were assessed by standard methods, while homocysteine was assessed by chemiluminescence. MetS was assessed using the updated NCEP-ATP III criteria. Disease activity was defined according to the International Ankylosing Spondylitis Assessment Study criteria. The 10-year CV risk (%) profile was evaluated in agreement to the Progetto Cuore criteria. No major CV event was detected in the study population. No significant differences were found when AS pts and controls were compared according to the mean a-IMT (0.52+/-0.26 vs 0.51+/-0.13 mm), max-IMT (0.92+/-0.20 vs 0.85+/-0.39 mm), prevalence of abnormal max-IMT >1 mm (27.2 vs 5.3%), and 10-year CV risk (9.9+/-9.6 vs 3.6+/-1.8%). Systolic blood pressure (p=0.04), triglyceride to HDL cholesterol ratio (p=0.002), and LDL cholesterol (p=0.03) were found significantly higher in AS pts than in controls; on the contrary, HDL cholesterol was pointed out as significantly lower (p<0.001). MetS was found in 11/24 (45.8%) AS pts and in 2/19 (10.5%) controls (p=0.019). No significant relationship emerged in MetS prevalence among AS pts regarding the mean value of age, disease duration, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Disease Activity Index, and the Italian version of Health Assessment Questionnaire. This preliminary report points out a higher prevalence of MetS in AS pts than in controls. Further studies are needed to confirm this finding.

Entities:  

Mesh:

Year:  2006        PMID: 16933103     DOI: 10.1007/s10067-006-0380-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  33 in total

1.  Impaired endothelial function in patients with ankylosing spondylitis.

Authors:  I Sari; T Okan; S Akar; H Cece; C Altay; M Secil; M Birlik; F Onen; N Akkoc
Journal:  Rheumatology (Oxford)       Date:  2005-10-04       Impact factor: 7.580

2.  The acute phase response does not fully predict the presence of insulin resistance and dyslipidemia in inflammatory arthritis.

Authors:  Patrick H Dessein; Barry I Joffe; Anne Stanwix; Andre S Botha; Zubair Moomal
Journal:  J Rheumatol       Date:  2002-03       Impact factor: 4.666

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 4.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  Richard Kahn; John Buse; Ele Ferrannini; Michael Stern
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

Review 5.  Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis.

Authors:  Mike J Peters; Irene E van der Horst-Bruinsma; Ben A Dijkmans; Michael T Nurmohamed
Journal:  Semin Arthritis Rheum       Date:  2004-12       Impact factor: 5.532

6.  [The global cardiovascular risk chart].

Authors:  Simona Giampaoli; Luigi Palmieri; Paolo Chiodini; Giancarlo Cesana; Marco Ferrario; Salvatore Panico; Lorenza Pilotto; Roberto Sega; Diego Vanuzzo
Journal:  Ital Heart J Suppl       Date:  2004-03

7.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.

Authors:  M Dougados; S van der Linden; R Juhlin; B Huitfeldt; B Amor; A Calin; A Cats; B Dijkmans; I Olivieri; G Pasero
Journal:  Arthritis Rheum       Date:  1991-10

8.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index.

Authors:  A Calin; S Garrett; H Whitelock; L G Kennedy; J O'Hea; P Mallorie; T Jenkinson
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

Review 9.  Blood pressure, systolic and diastolic, and cardiovascular risks. US population data.

Authors:  J Stamler; R Stamler; J D Neaton
Journal:  Arch Intern Med       Date:  1993-03-08

10.  Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women.

Authors:  Gang Hu; Qing Qiao; Jaakko Tuomilehto; Beverley Balkau; Knut Borch-Johnsen; Kalevi Pyorala
Journal:  Arch Intern Med       Date:  2004-05-24
View more
  28 in total

Review 1.  Atherosclerosis and endothelial dysfunction in patients with ankylosing spondylitis.

Authors:  V F Azevedo; R Pecoits-Filho
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

2.  Atherogenic index of plasma: a useful marker for subclinical atherosclerosis in ankylosing spondylitis : AIP associate with cIMT in AS.

Authors:  Erkan Cure; Abdullah Icli; Ali Ugur Uslu; Davut Sakiz; Medine Cumhur Cure; Rabia Aydogan Baykara; Fatma Yavuz; Sevket Arslan; Adem Kucuk
Journal:  Clin Rheumatol       Date:  2018-02-12       Impact factor: 2.980

3.  The coexistence of gout in ankylosing spondylitis patients: a case control study.

Authors:  Tal Gonen; Shmuel Tiosano; Doron Comaneshter; Howard Amital; Arnon D Cohen; Ora Shovman
Journal:  Rheumatol Int       Date:  2019-10-19       Impact factor: 2.631

Review 4.  Ankylosing spondylitis: Chinese perspective, clinical phenotypes, and associated extra-articular systemic features.

Authors:  Huei-Huang Ho; Ji-Yih Chen
Journal:  Curr Rheumatol Rep       Date:  2013-08       Impact factor: 4.592

5.  Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study.

Authors:  Gian Luca Erre; Pietro Sanna; Angelo Zinellu; Alessandra Ponchietti; Patrizia Fenu; Salvatore Sotgia; Ciriaco Carru; Antonello Ganau; Giuseppe Passiu
Journal:  Clin Rheumatol       Date:  2010-10-14       Impact factor: 2.980

6.  Atherosclerosis in male patients with ankylosing spondylitis: the relation with methylenetetrahydrofolate reductase (C677T) gene polymorphism and plasma homocysteine levels.

Authors:  Muharrem Geçene; Figen Tuncay; Pınar Borman; Dogan Yücel; Mehmet Senes; Behice Kaniye Yılmaz
Journal:  Rheumatol Int       Date:  2012-12-18       Impact factor: 2.631

7.  Serum homocysteine level in patients with ankylosing spondylitis.

Authors:  Bedriye Mermerci Başkan; Filiz Sivas; Lale Akbulut Aktekin; Yasemin Pekin Doğan; Kürşat Ozoran; Hatice Bodur
Journal:  Rheumatol Int       Date:  2009-03-15       Impact factor: 2.631

8.  Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease.

Authors:  Alessandro Giollo; Andrea Dalbeni; Giovanni Cioffi; Federica Ognibeni; Davide Gatti; Luca Idolazzi; Giovanni Orsolini; Pietro Minuz; Maurizio Rossini; Cristiano Fava; Ombretta Viapiana
Journal:  Clin Rheumatol       Date:  2017-09-09       Impact factor: 2.980

9.  Hyperhomocysteinemia in ankylosing spondylitis: prevalence and association with clinical variables.

Authors:  Laura Gonzalez-Lopez; Julia D Sanchez-Hernandez; Erika A G Aguilar-Chavez; Adolfo R Cota-Sanchez; Maria A Lopez-Olivo; Alberto I Villa-Manzano; Ricardo Ortega-Flores; Genadia L Espinoza-Magaña; Wendoline Rojo-Contreras; Ernesto G Cardona-Muñoz; Jorge I Gamez-Nava
Journal:  Rheumatol Int       Date:  2008-08-22       Impact factor: 2.631

Review 10.  Management of cardiovascular disease risk in chronic inflammatory disorders.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2009-04       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.